The pathophysiological and experimental substantiation for the use of a phytoneering drug for the treatment of acute respiratory viral infections and prevention of their complications
DOI:
https://doi.org/10.24959/cphj.20.1531Keywords:
phytoneering drug, Imupret®, acute respiratory viral infections, treatment, preventionAbstract
Despite the success achieved in the prevention and treatment of acute respiratory viral infections their annual prevalence exceeds the prevalence of the rest of the infectious diseases, and their portion in the overall structure of the infectious diseases reaches 90-95 %. Therefore, the development of new approaches to the treatment of acute respiratory viral infections and prevention of their complications remain a current urgent problem in practical medicine and pharmacy. Imupret® (“Bionoriсa”, Germany) contains BNO 1030 extract standardized by biologically active substances, obtained using a unique phytoneering technology from seven plant components, such as marshmallow root, chamomile flowers, horsetail grass, walnut leaf, yarrow grass, bark oak and dandelion herb; it is actively used to treat diseases of the upper respiratory tract (tonsillitis, pharyngitis, laryngitis), and prevent complications and relapses in acute respiratory viral infections. An important component of the pharmacodynamics of BNO 1030 is its antiviral and antibacterial effect. For many years, the European and domestic scientists have accumulated a solid database of scientific data that describe the complex positive effect of the active substance BNO 1030 on the immune system. The high scientific potential that underlies the concept of phytoneering allows us to create drugs not only of high quality, but also with high efficiency comparable to synthetic drugs of the similar action (comprehensive preclinical and clinical studies on the mechanisms of action, pharmacological effects, confirmation of efficacy and tolerability). At the same time, a scientifically based complex of various biologically active substances in a definite ratio provides the presence of a number of multidirectional effects (pleiotropy), which affect various functions of the body, including certain links of pathogenesis.
Conclusions. Imupret® is the drug of choice in the treatment of acute respiratory viral infections, for the prevention of their complications, as well as in the combination therapy of chronic upper respiratory tract infections. Its effectiveness in the treatment of acute respiratory viral infections and prevention of their complications has been substantiated by the pathogenetic mechanisms of the pharmacological action and proven by a number of experimental studies. The effectiveness and high safety of Imupret® have been confirmed by many years of the practical experience in wide medical practice, as well as a sufficient number of clinical trials of various phases and designs.References
Holubovska, O., Shkurba, V., Pechinka, A. (2012). Zdorovia natsii, 1, 129-140. Available at: http://nbuv.gov.ua/UJRN/Uzn_2012_1_23
World Health Organization. (n.d). Mortality and global health estimates. Available at: https://www.who.int/gho/mortality_burden_disease/en/
Trykhlib, V., Zadorozhna, V., Tkachuk, S., Operchuk N. (2016). Osoblyvosti zakhvoriuvanosti na hostri infektsii verkhnikh dykhalnykh shliakhiv mnozhynnoi ta neutochnenoi lokalizatsii sered naselennia za administratyvnymy rehionamy Ukrainy. Proceeding from Infektsiini khvoroby v praktytsi likaria-internista: suchasni aspekty: materialy Vseukrainskoi naukovo-praktychnoi konferentsii (June 15-16, 2016). (pp. 191-195).Sumy: SumDU, 2016.
Bondarenko, A., Tikhomolova, E., Savinykh, M., Savinykh, N., Dekhtereva, N., Bobkov, A. (2012). Viatskii meditsinskii vestnik, 4, 3-5.
Savenkova, M. S, Savenkov, M. L, Afanaseva, A. A., Abramova, N. A. (2014). Pulmonologiia, 5, 83-93. doi: https://doi.org/10.18093/0869-0189-2014-0-5-83-93
Sisin, E. I. (2014). Sestrinskoe delo, 2, 45-48.
Karetkina, G. N. (2014). Poliklinika, 5 (1), 86-90.
Trykhlib, V. I., Zadorozhna, V. I., Tkachuk S. I., Operchuk, N. I., Palatna, L. O. (2006). Actual infectology, 3 (12), 83-92. doi: 10.22141/2312-413x.3.12.2016.81720.
The Center for Public Health of the Ministry of Health of Ukraine. (2020). Zakliuchna informatsiia shchodo pidsumkiv epidemichnoho sezonu z hrypu ta hostrykh respiratornykh infektsii 2019–2020 rokiv. Available at: https://phc.org.ua/sites/default/files/users/user90/flu_operinfo_2019-2020.pdf
Selye, H. (1956). The Stress of Life.New York: McGraw-Hill Book Company, 313.
Garkavi, L. Kh., Kvakina, E. B., Kuz’menko, T. S., Shihliarova, A. I. (2002). Antistressornye reaktsii i aktivatsionnaia terapiia. (Vol. 1). Ekaterinburg: Filantrop, 196.
Stupin, F. P., Tatkov, O. V. (2016) Nespetcificheskie adaptatcionnye reaktcii organizma i aktivatcionnaia terapiia v praktike vracha. Moscow: Izdatel’skie resheniia, 72.
Garkavi, L. Kh., Kvakina, E. B., Kuz’menko, T. S., Shihliarova, A. I. (2003). Antistressornye reaktsii i aktivatsionnaia terapiia. (Vol. 2). Ekaterinburg: Filantrop, 336.
Serheeva, I. V., Kamzalakova, N. I., Tikhonova, E. P., Bulyhin, H. V. (2012). Practical Medicine, 6 (61), 47-50.
Mokiia-Serbina, S. O., Vasylenko, N. V., Lytvynova, T. V., Shelevytska V. A. (2015). Klinichni rekomendatsii z diahnostyky, likuvannia ta profilaktyky HRVI u ditei rannoho viku. 2nd ed. Kryvyi Rih: R. A. Kozlov, 158.
Fashner, J., Ericson, K., Werner, S. (2012). Treatment of the common cold in children and adults. Am Fam Physician, 86 (2), 153‑159.
Drannik, G. N. (2006). Klinicheskaia immunoljhiia i alerholohіia.Kiev: Polihraf Plius, 510.
Chebotareva, T. A. (2012). Profilaktika grippa i drugih ostryh respiratornyh infekcij u detej vysokogo riska zabolevaemosti. Extended abstract of Doctor’s thesis.Moscow, 266.
Haraschenko, M. V. (2007) Novye tehnologii v medikamentoznoj profilaktike ostryh respiratornyh zabolevanij u detej shkol’nogo vozrasta v uslovijah megapolisa. Extended abstract of Candidate’s thesis.Moscow; 76.
Shamsheva, O. V., Boitsov, V. P. (2013). Lechaschii Vrach, (8), 92-94.
21. Instruktsiia dlia zastosuvannia IMUPRET® krapli. Available at: http://mozdocs.kiev.ua/likiview.php?id=20855
22. Instruktsiia dlia zastosuvannia IMUPRET® tabletky, vkryti obolonkoiu. Available at: http://mozdocs.kiev.ua/likiview.php?id=20856
23. Sait Derzhavnoho reiestru likarskykh zasobiv Ukrainy. Available at: http://www.drlz.com.ua/.
Zupanets, I.A., Sakharova T. S., Bezuhlaia, N. P. (2014). Medicine of Ukraine, 9 (185), 36-40.
Jur’ev, K. L. (2008). Ukrainian medical Journal, 3 (65), 93–105.
Berger, T. (2008). Tolerability and efficacy of a herbal combination preparation in children and adolescents with recurrent infections of the upper respiratory tract. MMW Fortschr Med, 26 (150), Suppl 2, 85-90.
Wagner, H. (1983). Medicinal plants as immunostimulants. Naturheilpraxis, 3, 256-262.
Wagner, H. (2000). Expert report. In: Tonsilgon — N Coated Tablets. Part III and IV. File 1. Pharmacological and toxicological documentation and Postmarketing surveillance studies and experience reports.Germany : Bionorica AG, 30.
Mel’nikov, O. F., Peleshenko, N. A., Zabolotnaia, D.D., Ryl’skaia, O. H. (2013). Immunomoduliatciia fitopreparatami v terapii vospalitelnykh zabolevanii verkhnikh dykhatelnykh putei (eksperimentalnye i kliniko-immunologicheskie issledovaniia). Kiev, 108.
Mel’nikov, O. F., Zabolotnyi, D.I.(2006). Zdorovia Ukrainy, 5, 136-137.
Mel’nikov, O. F., Ryl’skaia, O. H. (2005). Journal of Ear, Nose and Throat Diseases, 3, 74-76.
Mel’nikov, O. F. (1981). Immunologicheskie aspekty geneza khronicheskogo tonzillita i reguliatcii funktcionalnoi aktivnosti nebnykh mindalin. Doctor’s thesis. Kiev, 294.
Mel’nikov, O. F., Bredun A. Yu., Ryl’skaia, O. H., Peleshenko, N. A., Shmatko, V. I. (2012) Imunolohiia ta alerholohiia: nauka i praktyka, 3, 90-93.
Mel’nikov, O. F., Timchenko, S. V., Belousova, A. A., Timchenko, M. D. (2020). Pediatriia. Vostochnaia Evropa, 8 (1), 8-15.
Mel’nikov, O. F., Timchenko, M. D., Timchenko, S. V., Krasii, R. I. (2010). Journal of Ear, Nose and Throat Diseases, 5, 55-59.
Mel’nikov, O. F., Ryl’skaia, O. H., Zaiats, T. A., Pshenichkina, V. D., Prilutskaia, A. D., Litus, V. I. (2016). Zdorov’ia Ukrainy 21 storichchia, 4 (377), 73.
Mel’nikov, O. F., Ryl’skaia, O. H., Tsimar, A. V., Peleshenko, N. A. (2013). Medical Nature, 2 (14), 70-74.
Downloads
Published
Issue
Section
License
Copyright (c) 2020 National University of Pharmacy
This work is licensed under a Creative Commons Attribution 4.0 International License.
Authors who publish with this journal agree to the following terms:- Authors retain copyright and grant the journal right of first publication with the work simultaneously licensed under a Creative Commons Attribution License that allows others to share the work with an acknowledgement of the work's authorship and initial publication in this journal.
- Authors are able to enter into separate, additional contractual arrangements for the non-exclusive distribution of the journal's published version of the work (e.g., post it to an institutional repository or publish it in a book), with an acknowledgement of its initial publication in this journal.
- Authors are permitted and encouraged to post their work online (e.g., in institutional repositories or on their website) prior to and during the submission process, as it can lead to productive exchanges, as well as earlier and greater citation of published work (See The Effect of Open Access).
